Company Name of Executive Age Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-Term Compensation ($000) Total Direct Compensation ($000) Base Salary Prior FY ($000) Percent Change Base Salary (%) Potential Realizable Value of Option Grants ($000) FYE Value of Exercisable In-the-Money Options ($000) Percent of Co. Stock Owned By CEO (%) Cum. Total Return on Investment ($) Stock Price 12/31/02 ($) Stock Price 12/31/03 ($) Percent Change Stock Price (%) Shares Out (M
Executive Compensation Report | Monday, November 8, 2004
For The 214 CEOs In BioWorld's 231-Company Survey Who Received A Full Year Of Compensation Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) Stock Price 12/31/03 ($) Shares Out (M) Approx. Mkt. Cap. 12/31/03 ($M) 1 Kevin W. Sharer Amgen Inc. 1,098 2,475 3,573 61.79 1,293.00 79,896.30 2 Henri Termeer Genzyme Corp. 1,238 1,597 2,835 49.29 226.1 11,142.30 3 Tony White (21) Celera Genomics Group** 1,000 1,300 2,300 13.91 208.1 2,895.10 4
Executive Compensation Report | Sunday, November 7, 2004
Company Name of Executive Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-Term Comp. ($000) Total Direct Comp. ($000) Potential Realizable Value of Option Grants ($000) FYE Value of Exercisable In-the-Money Options ($000) Adolor Corp. Martha E. Manning 235 70 305 4 0 309 142 366 Affymetrix Inc. Barbara A. Caulfiend 363 170 533 13 0 546 0 1,161 Alexion Pharmaceuticals Inc. Thomas I.H. Dubin (1) 209 30 239 5 0 244 72 4 Arena Pharmaceuticals Inc
Executive Compensation Report | Tuesday, November 2, 2004
For The 64 Legal Officers In BioWorld's 231-Company Survey Who Received A Full Year Of Compensation Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) 1 Peter Wirth Genzyme Corp. 600 417 1,017 2 William G. Green Chiron Corp. 481 475 956 3 William B. Sawch (4) Celera Genomics Group** 423 360 783 4 Paul A. Mahon United Therapeutics Corp. 400 159 559 5 Barbara A. Caulfiend Affymetrix Inc. 363 170 533 6 John E. Osborn (5) Cephalon Inc
Executive Compensation Report | Tuesday, November 2, 2004
Company Name of Executive Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-Term Comp. ($000) Total Direct Comp. ($000) Potential Realizable Value of Option Grants ($000) FYE Value of Exercisable In-the-Money Options ($000) Acusphere Inc. (a) Charles P. Cox (1) 79 30 109 18 0 127 737 0 Advancis Pharmaceutical Corp. (a) Kevin S. Sly(2) 200 80 280 0 19 299 1,077 0 Aeolus Pharmaceuticals Inc. *** John P. Richert (3) 80 0 80 1 0 81 18 25 Albany
Executive Compensation Report | Tuesday, November 2, 2004
For The 51 Business And Corporate Officers In BioWorld's 231-Company Survey Who Received A Full Year Of Compensation Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) 1 Cubist Pharmaceuticals Inc. Oliver S. Fetzer (13) 354 100 454 2 Connetics Corp. John L. Higgins (10) 300 153 453 3 Incyte Corp. James P. Merryweather (23) 381 67 448 4 Lexicon Genetics Inc. Julia P. Gregory (26) 286 126 412 5 Biogen Idec Inc. Connie L. Matsui 301 104
Executive Compensation Report | Tuesday, November 2, 2004
Company Name of Executive Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-Term Comp. ($000) Total Direct Comp. ($000) Potential Realizable Value of Option Grants ($000) FYE Value of Exercisable In-the-Money Options ($000) Abgenix Inc. C. Geoffrey Davis 269 69 338 0 102 440 159 1,821 Access Pharmaceuticals Inc. David P. Nowotnik 227 24 251 6 0 257 44 245 Acusphere Inc. (a) Howard Bernstein (1) 234 50 284 0 44 328 367 631 Aeolus
Executive Compensation Report | Tuesday, November 2, 2004
For The 121 R&D Executives In BioWorld's 231-Company Survey Who Received A Full Year Of Compensation Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) 1 Roger M. Perlmutter Amgen Inc. 737 1,365 2,102 2 Norbert W. Bischofberger Gilead Sciences Inc. 483 428 911 3 Richard H. Scheller (22) Genentech Inc. 374 380 754 4 Geoffrey Duyk Exelixis Inc. 480 186 666 5 George D. Yancopoulos Regeneron Pharmaceuticals Inc. 476 165 641 6 Robert I
Executive Compensation Report | Tuesday, November 2, 2004
Company Name of Executive Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-Term Comp. ($000) Total Direct Comp. ($000) Potential Realizable Value of Option Grants ($000) FYE Value of Exercisable In-the-Money Options ($000) Aastrom Biosciences Inc.** Alan M. Wright (1) 182 0 182 0 0 182 74 0 Abgenix Inc. Kurt Leutzinger (2) 291 0 291 0 357 648 159 859 Accelrys Inc. John J. Hanlon (3) 275 0 275 24 0 299 293 100 Access Pharmaceuticals Inc
Executive Compensation Report | Tuesday, November 2, 2004
For The 167 CFOs In BioWorld's 231-Company Survey Who Received A Full Year Of Compensation Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) 1 Richard D. Nanula Amgen Inc. 658 1,040 1,698 2 Robert J. Hugin Celgene Corp. 483 475 958 3 Dennies L. Winger (15) Celera Genomics Group** 483 408 891 4 Michael S. Wyzga Genzyme Corp. 410 382 792 5 Louis J. Lavigne (35) Genentech Inc. 400 380 780 6 Shahram K. Rabbani (29) Enzo Biochem Inc
Executive Compensation Report | Tuesday, November 2, 2004
Rank Name of Executive Company Potential Realizable Value of Option Grants # ($000) No. of Securities UnderLying Options (000) % of Total Options Granted To Employees (%) Exercise or Base Price ($/Share) ## Stock Price 12/31/03 ($) 1 John McLaughlin (1) Corgentech Inc. (a) 18,868 775 14.3 1.2 16 2 Howard H. Pien Chiron Corp. 16,205 800 6.68 37.895 56.98 3 Gregory Lucier (2) Invitrogen Corp. 16,135 675 27.1 38.01 69.91 4 David Mott MedImmune Inc. 13,839 0 13
Executive Compensation Report | Sunday, October 31, 2004
CEOs Whose Total Direct Compensation Exceeded $2 Million Name of Executive Company Base Salary ($000) Bonus ($000) Other # ($000) Long-Term Compensation ## ($000) Total Direct Compensation ($000) Arthur Levinson (1) Genentech Inc. 860 1,204 80 21,014 23,158 Henri Termeer Genzyme Corp. 1,238 1,597 32 16,202 19,069 Stuart Essig Integra LifeSciences Holdings Corp. 403 0 2 17,454 17,859 John Martin Gilead Sciences Inc. 754 888 0 9,743 11,385 Kevin W. Sharer Amgen
Executive Compensation Report | Wednesday, October 27, 2004
Rank Name of Executive Company Bonus ($000) Base Salary ($000) Bonus As a Percent of Base Salary (%) Other ($000) Stock Price 12/31/02 ($) Stock Price 12/31/03 ($) Percent Change Stock Price (%) 1 Kevin W. Sharer Amgen Inc. 2,475 1,098 225.41 219 48.34 61.79 27.82 2 Henri Termeer Genzyme Corp. 1,597 1,238 129 32 29.57 49.29 66.69 3 Howard H. Pien (1) Chiron Corp. 1,500 552 271.74 261 37.6 56.98 51.54 4 Tony White (2) Celera Genomics Group** 1,300 1,000
Executive Compensation Report | Tuesday, October 26, 2004
For The Public Biotechnology Companies In BioWorld's Survey Number of companies: 231 Total number of employees at the 231 companies: 93,534 Average number of employees: 405 Median number of employees: 116 Total Market Capitalization of the 231 companies on Dec. 31, 2003: $282.2 billion Average Market Capitalization per company on Dec. 31, 2003: $1.2 billion Median Market Capitalization per company on Dec. 31, 2003: $254.4 million Smallest Market Capitalization on Dec. 31, 2003: $10.7
Executive Compensation Report | Thursday, October 21, 2004
Definitions & Methodology Using the same 231 proxy statements, we have gathered data on the compensation of executives responsible for legal affairs in the industry. The sample size of companies shrinks to 67 in the case of this position because many companies have no such position listed among the top wage earners. (Companies disclose compensation only for the five most highly paid executives or, in the case of small companies, for executives who earn more than $100,000.) A number companies
Executive Compensation Report | Thursday, October 21, 2004
Definitions & Methodology Using the same 231 proxy statements, we have gathered data on the compensation of executives responsible for business and/or corporate development in the industry. The sample size of companies shrinks to 56 in the case of this position because many companies have no such position listed among the top wage earners. (Companies disclose compensation only for the five most highly paid executives or, in the case of small companies, for executives who earn more than $100,000
Executive Compensation Report | Wednesday, October 20, 2004
Definitions & Methodology Using the same 231 proxy statements, we have gathered data on the compensation of executives responsible for Research & Development (R&D) in the industry. The sample size of companies shrinks to 129 in the case of this position because many companies have no such position listed among the top wage earners. (Companies disclose compensation only for the five most highly paid executives or, in the case of small companies, for executives who earn more than $100,000.) A
Executive Compensation Report | Wednesday, October 20, 2004
Definitions & Methodology Using the same 231 proxy statements, we have gathered data on the compensation of Chief Financial Officers (CFOs) in the industry. The sample size of companies shrinks to 167 in the case of CFOs because many companies have no CFO listed among the top wage earners. (Companies disclose compensation only for the five most highly paid executives or, in the case of small companies, for executives who earn more than $100,000.) A number companies have no such position at all
Executive Compensation Report | Wednesday, October 20, 2004
Company Name of Executive Age Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-Term Compensation ($000) Total Direct Compensation ($000) Base Salary Prior FY ($000) Percent Change Base Salary (%) Potential Realizable Value of Option Grants ($000) FYE Value of Exercisable In-the-Money Options ($000) Percent of Co. Stock Owned By CEO (%) Cum. Total Return on Investment ($) Stock Price 12/31/02 ($) Stock Price 12/31/03 ($) Percent Change Stock Price (%) Shares Out (M